Navigation Links
Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation

PHILADELPHIA, Feb. 20 /PRNewswire/ -- According to Anapol Schwartz ( attorney James Ronca (, a New England Journal of Medicine study ( (to be released in the February 21, 2008, print edition) confirms that Bayer AG's blood-clotting drug Trasylol(R), used in coronary artery bypass graft (CABG) procedures, causes kidney/renal failure and increases mortality risk. While initial findings of the study, commissioned by Bayer, were sent to the drug company and the FDA in 2006, this is the first time the final results have been published in full.

Ronca, who is one of the chairs of the national Trasylol(R) litigation, and represents a dozen families and victims (see Trasylol(R) lawsuit ( and a recent wrongful death complaint ( filed in Philadelphia), argues this study reinforces inherent problems in the FDA's screening process and opens the floodgates for additional litigation.

"According to published sources, thousands may have died from Trasylol(R), when this could have been prevented. Again, we have another example of the FDA not protecting the public -- and the safety of individuals taking a back seat to company profits," says Ronca, who leads advocacy initiatives to raise awareness about Trasylol's(R) side effects.

Pulled by Bayer from the market in November 2007 in response to FDA concerns, Trasylol(R) is administered by an anesthesiologist during CABG surgery ( to limit bleeding. Affected patients typically experience kidney/renal failure symptoms within 48 hours. Many, however, are unaware they have received the drug, complicating diagnosis.

"These findings should further educate the public about Trasylol's(R) dangers, and open the door for victims, and those who don't realize they are victims, to receive remuneration for their injuries," stresses Ronca, who has served as counsel to victims in product liability cases involving Baycol, LOTRONEX, hormone replacement therapy and breast implants.

Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley is a personal injury firm with law offices in Philadelphia, Reading, Media, and Harrisburg, Pa., as well as Cherry Hill, N.J. ( The firm is a multi-faceted practice with a tradition of excellence in medical malpractice law, pharmaceutical mass tort, toxic tort, class actions, products liability, automobile, securities and wrongful termination litigation. Since its founding in 1977, the firm has grown to over 30 attorneys, and compiled a record of success exceptional among its peers.

Contact: Alexandra Kane-Weiss/Jennifer Wasilisin


SOURCE Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Driven Healthcare Continues To Make Its Mark on Indianapolis Market
2. St.Vincent and Publicis Indianapolis Receive National Service Industry Advertising Awards
3. Brown Mackie College - Indianapolis Announces New Degree Program in Occupational Therapy
4. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
5. Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council
6. Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark
7. AHIP Statement on New York Attorney Generals Announcement
8. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
9. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
10. Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit
11. Statement from AAJ President Kathleen Flynn Peterson on ATRAs Latest Attack on Civil Justice Attorneys
Post Your Comments:
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target via ... “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a limited ... price. , IguanaMed’s mission is to outfit every healer around the world ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Safe storage for ... of two inventors, one from Lakewood, New Jersey and the other from Bradley Beach, ... patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often than ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 6th ... the University of British Columbia suggested that laws requiring bicyclists to wear helmets may ... part of the reason for the controversial conclusion is that, while helmets have certainly ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: